...
首页> 外文期刊>Trends in immunology >Biomarkers and immune-modulating therapies for Type 2 diabetes
【24h】

Biomarkers and immune-modulating therapies for Type 2 diabetes

机译:2型糖尿病的生物标志物和免疫调节疗法

获取原文
获取原文并翻译 | 示例
           

摘要

Recent advances in understanding the etiology of obesity, metabolic syndrome, and type 2 diabetes (T2D) have established involvement of the immune system. These developments highlight the potential of immunomodulatory therapies for treatment of these conditions. Here, we discuss current and new immunotherapeutic strategies for the treatment of T2D, the need for stratification of patients based on immune and autoimmune status, and biomarkers for evaluating treatment efficiency. The time has come to re-evaluate the clinical management of T2D patients using metabolic parameters alone, and to realize that patients should be stratified based on their immune and/or autoimmune status prior to initiation of therapy to realize fully the potential of immunomodulatory strategies for T2D.
机译:在了解肥胖症,代谢综合征和2型糖尿病(T2D)病因方面的最新进展已建立了免疫系统的参与范围。这些发展突显了免疫调节疗法在治疗这些疾病中的潜力。在这里,我们讨论了当前和新的T2D免疫治疗策略,基于免疫和自身免疫状态对患者进行分层的需求以及评估治疗效率的生物标记物。现在是时候单独使用代谢参数来重新评估T2D患者的临床管理,并意识到应该在开始治疗之前根据患者的免疫和/或自身免疫状态对患者进行分层,以充分实现免疫调节策略的潜力。 T2D。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号